ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Myopathies"

  • Abstract Number: 2074 • ACR Convergence 2024

    Experience on the Use of Obinutuzumab off Label in Patients with Refractory Idiopathic Inflammatory Myopathy

    Ivana Ilic1 and Galina Marder2, 1Northwell, Brooklyn, NY, 2Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY

    Background/Purpose: Idiopathic inflammatory myopathy (IIM) is a rare multisystem inflammatory condition leading to significant disability. The management of IIM remains challenging. B cell targeting therapies are…
  • Abstract Number: 0319 • ACR Convergence 2024

    Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis

    Farbod Moghaddam1, Mark Tarnopolsky2, Valérie Leclair3, marie Hudson3, Ross Mitchell4, Katherine Buhler1, Erin Hatcher5, Meifeng Zhang1, Antoine Dufour1, Luiz de Almeida1, Marvin Fritzler6 and May Choi1, 1University of Calgary, Calgary, AB, Canada, 2McMaster University, Hamilton, ON, Canada, 3McGill University, Montreal, QC, Canada, 4University of Alberta, Edmonton, Canada, 5McMaster University, Hamilton, Canada, 6Mitogen Diagnostics Corp, Calgary, AB, Canada

    Background/Purpose: Sporadic inclusion body myositis (sIBM) is often challenging to diagnose because many patients have no known biomarkers (seronegative). Machine learning was applied to identify…
  • Abstract Number: 1160 • ACR Convergence 2024

    Short Form-36 Psychometric Properties in Idiopathic Inflammatory Myopathies: Reliability, Validity and Responsiveness

    shiri keret1, Anushka Aggarwal2, Maha Almackenzie3, Tanya Chandra4, Raisa Silva5, Eugenia Gkiaouraki6, Nantakarn Pongtarakulpanit7, shreya Sriram6, Chester Oddis7 and Rohit Aggarwal8, 1Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, 2Department of Rheumatology, Indraprastha Apollo Hospital, New delhi, NY, 3Division of Rheumatology, Department of Medicine, Medical Cities of the Ministry of the Interior Riyadh, Saudi Arabia, Arlington, VA, 4University of Pittsburgh Medical Center, Pittsburgh, PA, 5Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 6Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 7Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: The quality of life, as measured by the Short Form-36 (SF-36), is reduced in patients with idiopathic inflammatory myopathies (IIM). Although endorsed by the…
  • Abstract Number: 2076 • ACR Convergence 2024

    Comparing the Efficacy of Conventional Immunosuppression and Rituximab in Anti-SRP Myositis: Insights from a Tertiary Care Centre Experience

    ABHILASHA ARVIND MANWATKAR1, Ajith Sivadasan2, adinair Vijakrishnan2, John Antony Jude Prakash3, chandhu aS4, JOHN KUMAR DAS5, Meera S N2, illiasul Ibad k2 and JOHN MATHEW1, 1christian medical college, vellore, Tamil Nadu, India, 2Christian Medical College, vellore, 3Chritian Medical College, Vellore, 4CMC Vellore, Vellore, Tamil Nadu, India, 5Christian Medical College, Vellore, India

    Background/Purpose:  There is a relative scarcity of studies on the effective management of Anti-signal recognition particle (anti-SRP)  myositis. Recent consensus on anti-SRP myositis shows that…
  • Abstract Number: 0327 • ACR Convergence 2024

    Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies

    Samuel Govea-Peláez1, Beatriz Alcalá-Carmona2, Jennifer Balderas Miranda3, Yatzil Reyna-Juárez2, María José Ostos-prado2, Nancy R Mejía-Domínguez2, Guillermo Juarez-Vega4, Jiram Torres Ruiz5 and Diana Gomez-martin6, 1INCMNSZ, Mexico City, Mexico, 2Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, 3Universidad Nacional Autónoma de México, Ciudad de México, Mexico, 4Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 5INCMNSZ, Mexico, Federal District, Mexico, 6INCMNSZ, Mexico City, Federal District, Mexico

    Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have reported chronic pain despite having normal serum muscular enzymes, physician global assessment (PhGA) and MMT8 scores, thus…
  • Abstract Number: 1161 • ACR Convergence 2024

    Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity

    Adriana Miguel-Álvarez1, luis M Amezcua Guerra2, María L Loredo-Mendoza1, Luis H. Silveira Torre3 and Angélica Vargas Guerrero4, 1Instituto Nacional de Cardiología "Ignacio Chávez", México, Distrito Federal, Mexico, 2Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, 3Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, 4Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico

    Background/Purpose: The aim of this study is to assess if there are clinical and serological differences in patients with idiopathic inflammatory myopathies (IIM) according to…
  • Abstract Number: 2078 • ACR Convergence 2024

    Increased RAGE Expression in Myositis

    Madison King1, Rita Spathis2, Elizabeth Bagley1 and Melissa Morales3, 1Binghamton University, Johnson City, NY, 2Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, NY, 3SUNY Binghamton, Johnson City, NY

    Background/Purpose: Myositis is a broad term for a group of rare autoimmune diseases that cause persistent muscle inflammation, weakness, and fatigue. Currently, first-line treatment for…
  • Abstract Number: 0332 • ACR Convergence 2024

    Predictors of Long-term Radiographic Changes in Patients with Idiopathic Inflammatory Myopathies Using Quantitative Imaging Analysis: Real World Experience from a Single Center Longitudinal Cohort

    Sangmee Bae1, Daniela Macrovic2, Auguestine Chung2, Jessica Channick2, Andrea Oh1, Jennifer Wang1, Ani Shahbazian2, Tiffany De Leon2, Yuna Lee2, Grace Kim2, Donald Tashkin2, Jonathan Goldin2 and christina Charles-Schoeman3, 1UCLA, Los Angeles, CA, 2UCLA, Los Angeles, 3UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of mortality in idiopathic inflammatory myopathies (IIM), and high-resolution computed tomography (HRCT) is a key modality…
  • Abstract Number: 1164 • ACR Convergence 2024

    IVIG Treatment Duration in Immune-mediated Necrotizing Myopathy and a Possible Association of Vacuolar Changes with Black/African American Female Patients

    Asim Mohamed1, Liron Caplan2 and Melissa Griffith3, 1PGY5, Aurora, CO, 2Rocky Mountain Regional VAMC, Aurora, CO, 3University of Colorado, Aurora, CO

    Background/Purpose: Immune Mediated Necrotizing Myopathy (IMNM) is a debilitating but understudied entity.  Correlations of demographic and clinical features with pathological findings remain underexplored.  In addition,…
  • Abstract Number: 2079 • ACR Convergence 2024

    Understanding Relapse Patterns in Anti-HMGCR Statin-induced IMNM: A Detailed Comparative Study

    Silvia Grazzini1, Angeles Galindo-Feria2, Edoardo Conticini1, Ingrid Lundberg3 and Maryam Dastmalchi4, 1Università di Siena, Siena, Italy, 2Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 3Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 4Karolinska University hospital, Stockholm, Sweden

    Background/Purpose: Statin-induced immune-mediated necrotizing myopathy (IMNM) is a recently recognized subtype of idiopathic inflammatory myopathy (IIM). This condition is marked by the sudden onset of…
  • Abstract Number: 0333 • ACR Convergence 2024

    Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease

    shiri keret1, Raisa Silva2, Irada Choudhuri2, Eugenia Gkiaouraki3, Tanya Chandra4, Nantakarn Pongtarakulpanit5, shreya Sriram3, silvia Martinez Laverde3, Dana Ascherman3, Siamak Mogahadam5, Chester Oddis5 and Rohit Aggarwal6, 1Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, 2Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 3Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 4University of Pittsburgh Medical Center, Pittsburgh, PA, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 6Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: Lung involvement is the most common and severe extra-muscular manifestation of Idiopathic Inflammatory Myopathies (IIM). Early identification of patients at risk for lung transplant…
  • Abstract Number: 1167 • ACR Convergence 2024

    Construction of a Refractory Myositis Predictive Index (ReMPI) in a Cohort of Patients with Idiopathic Inflammatory Myopathies

    Andres Gaytan Garcia de Alba1, Nancy R Mejía-Domínguez1, Yatzil Reyna-Juárez1, Beatriz Alcalá-Carmona1, María José Ostos-prado1, Agustin Hernandez Lopez1, Diana Gomez-martin2 and Jiram Torres Ruiz3, 1Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, 2INCMNSZ, Mexico City, Federal District, Mexico, 3INCMNSZ, Mexico, Federal District, Mexico

    Background/Purpose: An important proportion of patients with Idiopathic inflammatory myopathies (IIM) are at risk of developing refractory disease, which predispose them to cumulate damage, treatment…
  • Abstract Number: 2080 • ACR Convergence 2024

    HLA-DRB1*11:01 Association Differenciates Anti-hmgcr Immune-mediated Necrotizing Myopathy from Non-immune Mediated Statin Myotoxicity

    Cristina Corrales Selaya1, Diana Prieto-Peña2, gonzalo Ocejo-Viñals3, Carmen Secada Gómez4, alfonso Corrales-Martínez5, Carmen Ibarbia6, Zaida Salmón-gonzalez6, Marta Martín-millan6, Virginia Portilla-González6, Nerea mota-perez6, M. sebastian-mora gil6, J.C Batista-liz6, Veronica Pulito-Cueto7, Raquel Lopez-mejias7, Ricardo Blanco-Alonso8 and Jose Luis Hernandez6, 1Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 3Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, 4Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 5Hospital Universitario Marques de Valdecilla, Santander, Spain, 6Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 7IDIVAL, Santander, Spain, 8Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Genetic risk factors may explain why only a small proportion of patients taking statins develop severe cases of anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) immune-mediated necrotizing myopathy…
  • Abstract Number: 0337 • ACR Convergence 2024

    Characterization of Statin Induced Myopathy in the Hospital Setting

    Olivia Yang1, KUMAR VENKAT2, Jeffery Durbin3 and Scott Kubomoto1, 1Riverside Community Hospital, Riverside, CA, 2Voluntary Clinical Associate Professor of Medicine -UCRSOM, Riverside, California, IRVINE, CA, 3HCA Healthcare Physicians Services Group, Brentwood, TN

    Background/Purpose: Adverse effects of statin use involve the muscle and related rhabdomyolysis. Known risk factors for rhabdomyolysis include female sex, older age, Asian race, hypothyroidism,…
  • Abstract Number: 1169 • ACR Convergence 2024

    Efficacy of Intravenous Immunoglobulin (Octagam 10%) on Pulmonary Manifestations in Patients with Dermatomyositis: Results from the ProDERM Study

    Rohit Aggarwal1, christina Charles-Schoeman2 and Joachim Schessl3, and the ProDERM Investigators, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 2UCLA Medical Center, Santa Monica, CA, 3Friedrch-Baur-Institut; Ludwig-Maximilians University of Munich, Munich, Germany

    Background/Purpose: Interstitial lung disease (ILD) and other pulmonary manifestations are a major cause of mortality and morbidity in patients with dermatomyositis (DM). The ProDERM study…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology